Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
Reaction Biology Corp. is a CRO that specializes in epigenetic and kinase HTS and profiling services. RBC’s radioisotope based assays feature the largest collection of kinase & epigenetic targets available to the industry, including more than 559 kinases, 100+ reader domains, >30 methyltransferases, all HDACs and SIRTs, demethylases and more. RBC also produces high quality epigenetic proteins that are available for purchase.
The IvyGene test is a blood test that uses advanced DNA sequencing methods to detect the DNA methylation pattern of circulating tumor DNA (ctDNA) in blood samples in order to both confirm the presence of malignant cancer and to identify the cancer tissue of origin.
ACEA Biosciences Inc. produces cutting-edge cell analysis instruments. Our xCELLigence® RTCA systems enable label-free, real-time monitoring of cell proliferation, cell morphology, cell adhesion, cytotoxicity and cell invasion/migration. Our NovoCyte® benchtop flow cytometers include up to 17-parameter detection, volumetric cell counting, and autosampling at accessible price points. www.aceabio.com
Viracor Eurofins provides clinical trial biomarker testing services with expertise in custom assay transfer, design and validation for phase I-IV trials. Our CAP/CLIA and NY state accredited laboratory has over 30 years of experience in molecular testing, immune response monitoring, vaccine safety/efficacy assessment, allergy and hypersensitivity testing.
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
Using novel epigenetic technology, Epiontis provides precise and reproducible immunomonitoring services for clinical trials. The epigenetic PCR tests are based on in-house developed and IP protected markers specific for immune cell types (Treg, Th17, overall Tcells, etc.). Frozen whole blood or tissue can be used, permitting easy storage and logistics.